Oncternal Therapeutics to Participate in September Investor Conferences

NASDAQ Market News

NEXT STORY
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
PREV STORY
Oxurion NV Business & Financial Update – H1 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Orion’s statutory co-operation negotiations completed

ORION CORPORATION                               PRESS RELEASE                28 FEBRUARY 2018 at 10.45          Orion's statutory co-operation ...

author_avatar
NASDAQ Market News

Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)

author_avatar
NASDAQ Market News

Mesoblast Phase 2 Trial Results Show Early and Durable Effects of Single Mesenchymal Precursor Cell Infusion in Biologic Refractory Rheumatoid Arthritis Patients

NEW YORK and MELBOURNE, Australia, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) ...

author_avatar
NASDAQ Market News